Emily Capone

Chieti, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Journal: Molecular oncology

Published: June 16, 2025

LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth.

LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth.

Journal: Journal of translational medicine

Published: January 13, 2025

A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy.

A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy.

Journal: International journal of biological macromolecules

Published: January 09, 2025

Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.

Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.

Journal: Seminars in cancer biology

Published: December 01, 2023

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: November 03, 2023

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.

Journal: Oral oncology

Published: September 07, 2023

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target.

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target.

Journal: Cell death discovery

Published: August 13, 2023

HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications.

HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications.

Journal: Journal of pharmaceutical and biomedical analysis

Published: June 26, 2023

LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma.

LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma.

Journal: Oral diseases

Published: June 09, 2023

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.

Journal: Molecular pharmaceutics

Published: May 16, 2023

Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma.

Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma.

Journal: Molecular oncology

Published: January 11, 2023

MYC regulates metabolism through vesicular transfer of glycolytic kinases.

MYC regulates metabolism through vesicular transfer of glycolytic kinases.

Journal: Open biology

Published: December 01, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026